Valuation: Edesa Biotech, Inc.

Market Cap 6.82Cr 5.97Cr 5.51Cr 5.14Cr 9.69Cr 644.85Cr 9.86Cr 66Cr 26Cr 318.21Cr 26Cr 25Cr 1.11TCr P/E 2026 *
-4.62x
P/E 2027 * -3.82x
Enterprise Value 6.82Cr 5.97Cr 5.51Cr 5.14Cr 9.69Cr 644.85Cr 9.86Cr 66Cr 26Cr 318.21Cr 26Cr 25Cr 1.11TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day+5.15%
1 week+6.41%
Current month+12.60%
1 month+21.52%
3 months+52.53%
6 months+438.41%
Current year+472.54%
1 week 7.3
Extreme 7.3
8.89
1 month 4.56
Extreme 4.56
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
16/06Free

Founder

1,53,550 1.7268%
16/06Sell

Founder

1,53,530 1.7266%
01/06Free

Founder

1,671 0.0188%
Change 5-day change 1-year change 3-year change Capi.($)
+6.00%+6.41%+300.49%+43.23% 6.82Cr
+3.31%+1.93%+69.29%+129.27% 5.58TCr
-1.32%+16.55%+89.14%+101.41% 5.57TCr
-1.28%+2.68%-12.60%-13.79% 2.38TCr
+1.79%+4.38%+5.94%+405.31% 2.27TCr
+4.45%+8.43%+37.08%-29.19% 1.61TCr
+0.24%+5.98%+23.45%+184.72% 1.36TCr
+5.51%+22.37%+171.85%+333.54% 1.48TCr
+1.83%+4.58%+77.42%+132.45% 1.22TCr
-2.37%+6.47%+157.84%+161.16% 1.18TCr
Average +1.83%+6.80%+91.99%+144.81% 2.27TCr
Weighted average by Cap. +1.31%+5.03%+65.98%+142.25%

Financials

2026 *2027 *
Net sales - -
Net income -1.45Cr -1.27Cr -1.17Cr -1.1Cr -2.06Cr -137.44Cr -2.1Cr -14Cr -5.47Cr -68Cr -5.46Cr -5.34Cr -236.28Cr -2.65Cr -2.32Cr -2.14Cr -2Cr -3.77Cr -250.68Cr -3.83Cr -26Cr -9.98Cr -123.7Cr -9.96Cr -9.74Cr -430.95Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
01/26/01 $8.130 +6.00% 1,92,193
29/26/29 $7.670 -6.35% 75,183
26/26/26 $8.190 +9.64% 67,949
25/26/25 $7.470 -6.04% 1,30,275
24/26/24 $7.950 +4.06% 1,26,740
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.670USD
Average target price
16.33USD
Spread / Average Target
+112.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock